342 related articles for article (PubMed ID: 35223512)
1. SPINKs in Tumors: Potential Therapeutic Targets.
Liao C; Wang Q; An J; Zhang M; Chen J; Li X; Xiao L; Wang J; Long Q; Liu J; Guan X
Front Oncol; 2022; 12():833741. PubMed ID: 35223512
[TBL] [Abstract][Full Text] [Related]
2. Emerging Roles of SPINK1 in Cancer.
Räsänen K; Itkonen O; Koistinen H; Stenman UH
Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
[TBL] [Abstract][Full Text] [Related]
3. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
4. Novel inhibitory activity for serine protease inhibitor Kazal type-3 (Spink3) on human recombinant kallikreins.
Assis DM; Zalazar L; Juliano MA; De Castro R; Cesari A
Protein Pept Lett; 2013 Oct; 20(10):1098-107. PubMed ID: 23590280
[TBL] [Abstract][Full Text] [Related]
5. Expressional and functional analyses of epididymal SPINKs in mice.
Jeong J; Lee B; Kim J; Kim J; Hong SH; Kim D; Choi S; Cho BN; Cho C
Gene Expr Patterns; 2019 Jan; 31():18-25. PubMed ID: 30590135
[TBL] [Abstract][Full Text] [Related]
6. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
[TBL] [Abstract][Full Text] [Related]
7. Serine Protease Inhibitor Kazal Type 1 (SPINK1) Promotes Proliferation of Colorectal Cancer Through the Epidermal Growth Factor as a Prognostic Marker.
Chen YT; Tsao SC; Yuan SS; Tsai HP; Chai CY
Pathol Oncol Res; 2015 Sep; 21(4):1201-8. PubMed ID: 26037168
[TBL] [Abstract][Full Text] [Related]
8. Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions.
Räty S; Sand J; Laukkarinen J; Vasama K; Bassi C; Salvia R; Nordback I
Pancreatology; 2013; 13(5):530-3. PubMed ID: 24075519
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma.
Räsänen K; Lehtinen E; Nokelainen K; Kuopio T; Hautala L; Itkonen O; Stenman UH; Koistinen H
Mol Carcinog; 2016 Dec; 55(12):2010-2023. PubMed ID: 26663388
[TBL] [Abstract][Full Text] [Related]
10. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
11. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
Ohmuraya M; Yamamura K
Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
[TBL] [Abstract][Full Text] [Related]
12. Do genetic variants in the SPINK1 gene affect the level of serum PSTI?
Kume K; Masamune A; Ariga H; Hayashi S; Takikawa T; Miura S; Suzuki N; Kikuta K; Hamada S; Hirota M; Kanno A; Shimosegawa T
J Gastroenterol; 2012 Nov; 47(11):1267-74. PubMed ID: 22526274
[TBL] [Abstract][Full Text] [Related]
13. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.
Mehner C; Oberg AL; Kalli KR; Nassar A; Hockla A; Pendlebury D; Cichon MA; Goergen KM; Maurer MJ; Goode EL; Keeney GL; Jatoi A; Sahin-Tóth M; Copland JA; Radisky DC; Radisky ES
Oncotarget; 2015 Nov; 6(34):35737-54. PubMed ID: 26437224
[TBL] [Abstract][Full Text] [Related]
14. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
15. The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant.
Buchholz I; Nagel F; Klein A; Wagh PR; Mahajan UM; Greinacher A; Lerch MM; Mayerle J; Delcea M
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140281. PubMed ID: 31525466
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic secretory trypsin inhibitor: More than a trypsin inhibitor.
Wang GP; Xu CS
World J Gastrointest Pathophysiol; 2010 Jun; 1(2):85-90. PubMed ID: 21607145
[TBL] [Abstract][Full Text] [Related]
17. Functional Roles of SPINK1 in Cancers.
Lin TC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
[TBL] [Abstract][Full Text] [Related]
18. Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer.
Koskensalo S; Louhimo J; Hagström J; Lundin M; Stenman UH; Haglund C
PLoS One; 2013; 8(10):e76906. PubMed ID: 24204699
[TBL] [Abstract][Full Text] [Related]
19. High Prevalence of Serine Protease Inhibitor Kazal Type 1 Gene Variations Detected by Whole Gene Sequencing in Patients with Fibrocalculous Pancreatic Diabetes.
Kolly A; Shivaprasad C; Pulikkal AA; Atluri S; Sarathi V; Dwarakanath CS
Indian J Endocrinol Metab; 2017; 21(4):510-514. PubMed ID: 28670531
[TBL] [Abstract][Full Text] [Related]
20. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
